EUCTR2014-000986-30-IT
Active, not recruiting
Not Applicable
Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Angioid Streaks (EYLEA-STRIE) - EYLEA-STRIE
IRCCS Ospedale San Raffaele U.O. Oculistica0 sitesMay 20, 2014
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- IRCCS Ospedale San Raffaele U.O. Oculistica
- Status
- Active, not recruiting
- Last Updated
- 10 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men and women \= 18 years of age
- •Presence of CNV associated with angioid streaks, naïve or previously treated with exudative manifestations involving the fovea
- •Best\-corrected visual acuity (BCVA) between 20/400 and 20/25\.
- •Signed Informed Consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 10
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 20
Exclusion Criteria
- •Prior antiangiogenic treatment within 30 days prior the Screening
- •Hypersensitivity to the active substance or to any of the excipients
- •ocular or periocular infection suspected or in progress
- •severe intraocular inflammation in progress
- •Inability to document the lesion with retinography, retinal fluorescein angiography (FAG), autofluorescence, optical coherence tomography (OCT) for media opacities, allergy to dyes, lack of venous access.
- •Any other medical condition of the eye that can irreversibly affect the visual acuity in the study eye, including amblyopia, ischemic optic neuropathy, clinically significant diabetic macular edema, severe nonproliferative diabetic retinopathy
- •Women who are pregnant or breastfeeding. Women of childbearing age will be excluded unless they make use of contraceptive during treatment and for at least 3 months after the last injection of intravitreal Aflibercept
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Optical Coherence Tomography Angiography Biomarkers in a Bi-monthly Maintenance Dosing Aflibercept in Patients with Neovascular Age-Related Macular DegeneratioDiseases of the eye and adnexaKCT0007375Kyung Hee University Hospital40
Not yet recruiting
Phase 3
To investigate the role of Intravitreal Aflibercept (Eylea) in the treatment of patients whose wet Age related Macular degeneration is not adequately controlled with conventional anti VEGF (intravitreal Avastin or Lucentis) treatment.ACTRN12613001020774Greenlane Clinical Centre Auckland District Health Board50
Active, not recruiting
Phase 1
Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticumChoroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticumMedDRA version: 20.0Level: PTClassification code 10037150Term: Pseudoxanthoma elasticumSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2014-005263-33-DEMedizinische Fakultät der Universität Bonn15
Not yet recruiting
Not Applicable
To study the safety and efficacy of Pegaptanib eye injection in the treatment of retinal bleeding due to myopiaCTRI/2011/07/001919VPrasad Eye Institute20
Unknown
Phase 2
Intravitreal Conbercept for Idiopathic Choroidal NeovascularizationIdiopathic Choroidal NeovascularizationNCT02857517Jiao Mingfei50